Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO
Authors:
- Sabine HeubleinSHSabine Heublein
- Joanna BaumJBJoanna Baum
- Anna JaegerAJAnna Jaeger
- Donata Grimm-GlangDGDonata Grimm-Glang
- Julia OlthoffJOJulia Olthoff
- Elena Ioana BraicuEBElena Ioana Braicu
- Osama Azzam NietoONOsama Azzam Nieto
- Kathrin HassdenteufelKHKathrin Hassdenteufel
- Barbara SchmalfeldtBSBarbara Schmalfeldt
- Lars HankerLHLars Hanker
- Markus WallwienerMWMarkus Wallwiener
- Andreas SchneeweissASAndreas Schneeweiss
Open Access
Abstract
Background: Surgery is the backbone of early-stage ovarian cancer (OC) management. However, in practice, there is disagreement about the extent of surgical staging and whether additional adjuvant treatment should be provided. As omitting relevant diagnostic or therapeutic procedures might lead to undertreatment, we aimed to structurally investigate treatment practice in addition to prognostic factors in a multicentre series of patients (pts) diagnosed with early-stage OC. Patients: Within this retrospective, multicentre study, medical records of 379 pts who had undergone surgery for suspected early-stage OC between January 2014 and March 2020 were analysed. Results: Of the 379 patients, 292 had pT stage 1a-2a and had complete data on the extent of surgical staging. At least one surgical step was omitted in 100 pts (34.2%). Complete surgical staging (n = 192; (65.8%)) was more often performed in high-grade serous OC and was independent of the healthcare level of the hospital where the initial diagnosis was made. Missing to take peritoneal biopsies was associated with reduced relapse-free-survival in incompletely staged, pT1 cases (p = 0.03). About every second patient (46.7%) with a final stage lower than FIGO IIB and treated with adjuvant chemotherapy received combination chemotherapy. BRCA1 and BRCA2 testing was only performed in a subset of pts, and mutations were detected in 18% (14/79) and 9% (7/85) pts, respectively. Conclusions: This study helps to increase our understanding of early-stage OC treatment and prognosis. In addition to treating patients in compliance with current guidelines, the need for BRCA testing should also be considered for early-stage OC.Keywords
Funding Information
- NOGGO (Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie)
- Deutsche Forschungsgemeinschaft
This publication has 22 references indexed in Scilit:
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerCancer Discovery, 2015
- Optimal treatment of early-stage ovarian cancerAnnals of Oncology, 2014
- Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: Implications for surgical stagingGynecologic Oncology, 2011
- Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish populationAnnals of Oncology, 2010
- Surgical Staging and Treatment of Early Ovarian Cancer: Long-term Analysis From a Randomized TrialJNCI: Journal of the National Cancer Institute, 2010
- Treatment for Recurrent Ovarian Cancer—At First RelapseJournal of Oncology, 2009
- Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm TrialJNCI: Journal of the National Cancer Institute, 2003
- The Benefits of Comprehensive Surgical Staging in the Management of Early-Stage Epithelial Ovarian CarcinomaGynecologic Oncology, 2002
- Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?Gynecologic Oncology, 1990
- Adjuvant Therapy in Stage I and Stage II Epithelial Ovarian CancerNew England Journal of Medicine, 1990